thought call
number move part gilead result
overal messag revenu growth inde margin posit
follow declin revenues/non-gaap ep inde weve model
growth product revenu non-gaap ep along
pipelin expans support gilead recent re-rat conserv tone
growth mostli relat ranexa/ letairi plu price eros
hiv may caus near-term investor uncertainti ultim gilead stori
today pipelin expans nash selonsertib two phase trial
filgotinib two phase trial ra descovi prep phase hiv prevent
read vastli differ set-up prior year come
time certainti gilead hiv busi given biktarvi robust
launch hep revenu much smaller stabl major
commerci uncertainti yescarta hit tip point two quarter
modest q/q growth overal like gilead invest profil new
ceo oday start march reason valuat estim peer
expand pipelin bd/m increasingli like solid
underli core franchis hiv continu domin treatment
landscap drive growth maintain ow pt
pipelin updat phase filgotinib ra studi finch track
readout potenti file late earli enrol complet
phase uc crohn continu enrol readout nash phase
selonsertib stellar stellar similarli remain trackwith
phase doublet combin data atla anticip data phase
descovi prep discov trial also like
model adjust follow call forecast revenu
respect maintain
non-gaap ep estim lower outlook
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
